Using glucocorticoids, rituzimab, or certain immunosuppressants to treat connective tissue diseases is associated with greater risks for severe COVID-19-related outcomes.

Topline results were announced from a phase 2/3 trial evaluating linsitinib for the treatment of moderate to severe thyroid eye disease.

COVID-19 was associated with more severe disease outcomes than influenza or respiratory syncytial virus (RSV) during the 2022 to 2023 season.

A slew of recalled OTC eye drops during the past 2 years has diminished patient trust, but optometrists are equipped to restore it.

People still see COVID-19 as an ongoing public health threat, even though the pandemic officially ended in 2023.

Fasting plasma glucose (FPG), age, body mass index (BMI), and male sex are all associated with development of diabetes.

A popular diabetes drug just got a major new approval -- and it could be a game-changer for millions of Americans at risk for kidney failure.